CRYOTHERAPY
ApprovedSmall molecule
CRYOTHERAPY is one of 23 small molecule programs targeting Common Wart. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Common Wart
#DrugCompanyPhaseTrials
1Vistide
GileadApproved
Active
PfizerPhase 3
CRYOTHERAPY
AAssistance Publique - Hôpitaux de Paris
Approved
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 2
Tuberculin Purified Protein Derivative
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Resiquimod
GGraceway Pharmaceuticals, LLC
Phase 2
CLS006
MMaruho Co., Ltd.
Phase 3
A-101
AAclaris Therapeutics, Inc.
Phase 2
Trexall
Alnylam PharmaceuticalsPreclinical
PEP005
LEO PharmaPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Common Wart1 trial
Comparison of Cryotherapy and Peeling Agent in the Treatment of Common Warts
Completed·—·N/A·NCT05712811·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CRYOTHERAPY. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details